Discover how DecisionDx-UM offers personalized prognostic insights for uveal melanoma

The DecisionDx-UM gene expression profile (GEP) test enables accurate determination of metastatic risk in uveal melanoma. The test identifies the molecular signature of an individual’s tumor and its likelihood of metastasis within 5 years. Specifically, the assay determines the activity or “expression” of 15 genes which indicate a patient’s individual risk, or class.

Metastatic risk assessment is critical in Uveal Melanoma

Uveal melanoma is a rare but serious eye cancer, with about 2,000 new cases in the U.S. each year.

Although the primary tumor is successfully treated in over 90% of cases, up to half of patients will eventually develop metastatic disease - making early, accurate assessment of metastatic risk essential for guiding surveillance and care decisions.

Genomic testing that defines the standard of care in Uveal Melanoma

Castle’s comprehensive genomic testing has transformed the management of uveal melanoma. The DecisionDx®-UM gene expression profile (GEP) test is the most extensively validated prognostic test for this disease, helping identify patients at low or high risk of metastasis so physicians can tailor surveillance and treatment plans. Since its introduction in 2009, GEP testing has been adopted by the majority of U.S. ocular oncology specialists as the standard of care for guiding risk-appropriate management decisions.

Add-on testing for DecisionDx®-PRAME (PRAME gene expression) and DecisionDx®-UMSeq (DNA mutation status) provide additional genomic insights and can be run on the same tumor sample as the DecisionDx-UM test.

The need for accurate molecular prognostic testing

Traditional staging does not adequately stratify patient for risk-based management decisions.

12% 15 year mortality in lowest-stage tumors
Historically, most physicians performed intensive surveillance on their UM patients
Molecular classification with GEP has changed the paradigm by grouping patients into clinically actionable risk groups
Patients want to know their risk

90% of patients wanted prognostic info at diagnosis; 99% found value in their test results.

Changing how uveal melanoma is managed

DecisionDx-UM identifies which patients are at low or high risk for the progression of their disease so their physicians can appropriately adjust the level of care provided.

Since its introduction in late 2009, it has been adopted as the standard of care by the majority of ocular oncology specialists in the U.S. to inform risk-appropriate clinical care decisions.